InsiderTrades.com logo

INBX Insider Trading

Insider Ownership Percentage: 22.20%
Insider Buying (Last 12 Months): $3,618,717.42
Insider Selling (Last 12 Months): $10,290,000.00

Inhibrx Insider Trading History Chart

This chart shows the insider buying and selling history at Inhibrx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Inhibrx Share Price & Price History

Current Price: $11.47
Price Change: +0.30 (1.20%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for INBX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$11.47Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Inhibrx (NASDAQ:INBX)

82.46% of Inhibrx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INBX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$78kbought$451ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$60M-$40M-$20M$0$20M$40M$60MTotal InflowsTotal Outflows
Inhibrx logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Read More on Inhibrx

Today's Range

Now: $11.47
Low: $11.25
High: $11.79

50 Day Range

MA: $13.15
Low: $11.32
High: $14.72

52 Week Range

Now: $11.47
Low: $10.80
High: $34.83

Volume

84,648 shs

Average Volume

203,362 shs

Market Capitalization

$166.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Inhibrx?

Inhibrx's top insider shareholders include:
  1. Brendan P Eckelman (Insider)
  2. Jon Faiz Kayyem (Director)
  3. Mark Lappe (CEO)
  4. Global Investors Lp Viking (Major Shareholder)
  5. Kristiina Md Vuori (Director)
Learn More about top insider investors at Inhibrx.

Who are the major institutional investors of Inhibrx?

Inhibrx's top institutional shareholders include:
  1. Alpha Wealth Funds LLC — 0.27%
  2. GAMMA Investing LLC — 0.05%
Learn More about top institutional investors of Inhibrx stock.

Which major investors are selling Inhibrx stock?

Within the last quarter, INBX stock was sold by these institutional investors:
  1. Alpha Wealth Funds LLC

Which major investors are buying Inhibrx stock?

During the last quarter, INBX stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
During the previous year, these company insiders have bought Inhibrx stock:
  1. Brendan P Eckelman (Insider)
  2. Jon Faiz Kayyem (Director)
  3. Mark Lappe (CEO)
  4. Global Investors Lp Viking (Major Shareholder)
Learn More investors buying Inhibrx stock.